

# WEEKLY EPIDEMIOLOGICAL REPORT

# A publication of the Epidemiology Unit Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Vol. 51 No. 36

31st - 06th Sep 2024

#### **Brucellosis - Part II**

This is the second article of two in a series on "Brucellosis"

#### Clinical manifestation

Brucellosis typically presents with a wide range of symptoms. The incubation period is often unclear but generally lasts between 2 to 4 weeks. The disease may begin gradually or suddenly, and subclinical infections are frequently observed. Common symptoms include fever, chills, loss of appetite, sweating, weakness, fatigue, and pain in the joints, muscles, or back, along with headaches. Brucellosis symptoms

may come and go over weeks or months, and in some cases, individuals may develop chronic brucellosis, experiencing symptoms for years

even after treatment. Long-term symptoms may include persistent fatigue, recurring fevers, endocarditis, arthritis, spondylitis, and sacroiliitis. Due to the vague and often mild symptoms of brucellosis, diagnosis is frequently overlooked in many patients.




Photo credit- https://almostadoctor.co.uk/encyclopedia/brucellosis

Contents	Page
1. Brucellosis- Part II	1
2. Summary of selected notifiable diseases reported $(24^{th} - 30^{th}  {\rm Aug}  2024)$	3
3. Surveillance of vaccine preventable diseases & AFP (24th – 30th Aug 2024)	4

#### Complication

Brucellosis can lead to complications affecting various parts of the body, including the reproductive system, liver, heart, and central nervous system. Chronic cases may result in complications localized to a single organ or spread throughout the body. One of the most severe complications is endocarditis, which can damage or destroy heart valves if left untreated and is the leading cause of brucellosis-related deaths. Joint inflammation, particularly in the knees, hips, ankles, wrists, and spine, can cause pain, stiffness, and swelling, while spondylitis and sacroiliitis are especially difficult to treat. In males, brucellosis may infect the epididymis, potentially spreading to the testicles, and causing epididymo-orchitis. The disease may also affect the spleen and liver, causing enlargement, and in some cases, it can lead to life-threatening central nervous system infections like meningitis or encephalitis.

#### **Diagnosis**

A clinical diagnosis can be made if there is a history of exposure, but confirmation of Brucella infections requires laboratory tests such as culture, serological tests, or nucleic acid amplification assays. The gold standard is culture, where Brucella can be isolated from blood, bone marrow, or other body fluids, though this process can be time-consuming. Serological tests are widely used, including the Standard Agglutination Test (SAT) to detect antibodies, and ELISA to measure specific immunoglobulins like IgM and IgG. The Rose Bengal Test (RBT) is a rapid screening tool commonly used in resource-limited settings, while the Coombs test can be employed when agglutination test results are inconclusive. Nucleic acid amplification tests (NAATs) such as PCR are highly sensitive and specific, enabling rapid detection of Brucella DNA.

#### **Treatment**

Treatment options include doxycycline 100 mg twice daily for 45 days, combined with streptomycin 1 g daily for 15 days. An alternative regimen involves doxycycline for 45 days, paired with rifampicin for the same duration. While gentamicin may be used as a substitute for streptomycin, there is currently no direct study comparing these two regimens. The optimal treatment for pregnant women, neonates, and children under 8 remains uncertain. For children, treatment options may include co-trimoxazole in combination with an aminoglycoside (streptomycin or gentamicin) or rifampicin.

## PREVENTION AND CONTROL

Brucellosis prevention relies on monitoring and mitigating risk factors. The most effective approach is to eradicate the infection in animals. Vaccination of cattle, goats, and sheep is advised in areas with high prevalence. In regions with lower prevalence, serological testing and culling can also be beneficial. In countries where vaccinating or removing infected animals is not practical, preventing human infection focuses on increasing awareness, ensuring food safety, and maintaining

good hygiene practices in occupational settings and laboratories.

Pasteurizing milk—both for direct consumption and for making dairy products like cheese—is crucial to prevent transmission from animals to humans. Effective education campaigns and policies promoting the avoidance of unpasteurized milk products can help in this regard.

In agricultural and meat-processing environments, using protective measures (eg, masks, gloves, aprons, and eye protection) and properly handling and disposing of afterbirths, animal carcasses, and internal organs are key strategies for prevention.

Brucellosis is the most frequently reported bacterial infection associated with laboratory work. If you work in a lab, it's important to take precautions when handling samples to avoid infection

### Compiled by:

Dr Helanka Wijayatilake Senior Registrar Epidemiology Unit

#### **References:**

- 1. https://www.who.int/news-room/fact-sheets/detail/brucellosis
- https://emedicine.medscape.com/article/213430-treatment? form=fpf
- Yagupsky P, Morata P, Colmenero JD. Laboratory Diagnosis of Human Brucellosis. Clinical Microbiology Reviews. 2019 Dec;33(1):e00073–19.
- 4. Medical Microbiology. 4th edition. Chapter 28 Brucella, G.G. Alton and J.R.L. Forsyth.
- Centres for Disease Control and Prevention. Estimates human Brucella infections could be four times higher than previously thought. Food Safety; 2023.
- Pappas G, Papadimitriou P, Akritidis N, et al.. The new global map of human brucellosis. Lancet Infect Dis. 2006 Feb;6(2):91– 99. doi: 10.1016/S1473-3099(06)70382-6
- Long ignored but making a comeback: a worldwide epidemiological evolution of human brucellosis, Zhiguo Liu, a,\* Liping Gao,b,\* Miao Wang,c Min Yuan, a and Zhenjun Lia,d, Emerging Microbes Infection. 2024; 13(1): 2290839.
- Madalagama R. Identification of biovars of Brucella abortus in aborted cattle and buffaloes herd in Sri Lanka. Veterinary World. 2011;4(12):542–545.
- 9. Rossetti CA, Maurizio E, Rossi UA.. Comparative review of Brucellosis in small domestic ruminants. Front Vet Sci. 2022;9:887671. doi: 10.3389/fvets.2022.887671
- Lashley FR. Emerging infectious diseases at the beginning of the 21st century. Online J Issues Nurs. 2006 Jan 31;11(1):2. doi: 10.3912/OJIN.Vol11No01Man01

Table 1: Selected notifiable diseases reported by Medical Officers of Health 17th - 23rd Aug 2024 (35th Week)

ıab	ושו	. ა	HEC	ted	HOU	IIab	ie u	IISE	ises	rep	oorte	eu L	y IV	ear	cai	OTH	cers	01 1	пеа	III	1/ <sup>tn</sup>	-23	" A	ug 2	<b>202</b> 4	. (3	J 1	vee	K)
e	*5	100	66	100	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	66	
WRCD	<u>*</u>	89	100	93	100	100	85	22	100	82	93	100	100	100	100	62	22	92	100	100	96	100	88	100	92	80	85	92	
losis	В	1479	831	420	452	88	185	302	115	111	187	18	4	, 56	23	109	94	62	364	146	206	80	163	,	232	255	86	6122	
Tuberculosis	⋖	43	56	7	17	က	က	7	22	7	7	0	0	0	0	7	_	0	က	0	9	0	2	7	12	တ	က	177	
nania-	В	2	19	~	41	229	_	က	361	06	~	~	~	6	10	4	20	16	452	28	643	389	31	187	132	21	0	2692	
Leishmania-	A	~	က	0	∞	15	0	0	2	2	0	~	0	_	_	0	0	~	6	~	13	∞	<u></u>	∞	0	0	0	75	
ngitis	В	30	66	46	13		15	65	23	63	18	9	က	19	2	39	32	14	209	54	41	26	28	78	102	51	12	110	
Meningitis	⋖	~	2	~	0	~	0	0	0	~	~	_	0	_	0	~	_	2	2	0	_	<del></del>	<del>-</del>	7	က	0	0	28	
Chickenpox	В	383	298	462	307	117	186	265	250	270	162	8	7	33	4	93	95	29	393	107	205	113	273	97	246	652	179	5572	
Chick	A	17	_	22	3	2	7	24	9	6	~	_	_	0	0	3	0	2	6	2	4	9	2	4	4	12	7	152	
H. Rabiies	В	0	0	_	_	0	0	_	2	0	~	2	0	0	_	2	_	0	4	_	_	0	0	_	2	_	0	22	
H. R	4	0	0	0	0	0	0	0	0	0	0	~	0	0	_	0	0	0	0	0	0	0	0	0	0	0	0	7	
Viral Hep.	В	00	00	00		2	9	6	9	9	7	0	_	4	0	17	2	3	4	4		45	24	33	20	0	4	258	
Vir	⋖	0 ~	0	0	~	0	0	2	0	2	- 2	0	0	0 1	0	0	0	0	0	_	~	4	7	4	0	0	0	18	
Typhus F.	α .	0 8	0 8	4	2 28	0 2	1 34	7 91	0 40	0 20	1 441	1	0 11	0 4	0 11	0 2	0	0 12	1 20	3 27	1 28	0 2	2 32	0 25	1 22	0 23	0 5	21 916	
	A	369	530	535	191	78	143	295	363	355	17	18	21	92	29	61	158	131	482	189	333	217	399	268	1320	531	62		
Leptospirosis	A B	16 30	16 53	8 5;	7 19	<b>←</b>	0	20 50	5 3(	14 39	0	0	0	0	<b>←</b>	<u></u>	9 11	0 1;	11 48	2 18	9	4 2	2 39	5 5(	30 13;	10 53	0	165 7776	
50		19		36	54	20	201		45	56	34	2	0	21	17	53	17	7	346	က	38	7	31	84	15	<del></del>	16	0	
F. Poisonin	A B	0	_	<b>←</b>	0	0	1	4	_	0	<b>←</b>	0	0	0	0	_	0	2	7	0	0	0	0	0	0	0	<sub>∞</sub>	21 1260	
	/ B	46	13	30	6	7	0	10	2	7	23	2	<u></u>	_	0	9	0	က	3	က	7	~	2	က	ω	0	~	202	
En. Fever	⋖	0	0	0	0	0	0	~	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
alitis	В	7	26	7	7	~	7	20	က	9	7	0	0	_	0	10	က	~	31	က	9	2	9	က	2	9	0	153	
Encephalitis	⋖	0	~	0	0	~	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	~	~	0	0	0	0	9	
	В	26	33	21	32		109	41	26	∞	52	13	7	12	∞	66	27	13	38	7	25	18	26	15	85	13	16	781	
Dysentery	∢	7	0	0	0	0	7	0	_	0	7	7	0	0	_	က	0	0	0	0	7	0	0	0	4	0	0	19	
Fever	В	8448	3867	2137	3406	292	279	1591	671	741	5208	286	246	162	194	1368	222	617	1866	006	623	310	701	636	2169	1628	655	39498	
Dengue Fever	4	250	122	22	94	∞	4	20	15	13	15	~	ω	0	2	29	2	∞	20	17	∞	7	20	18	48	23	12	854	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.Ik). T=Timeliness refers to returns received on or before 23rd Aug, 2024 Total number of reporting units 358 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

24th - 30th Aug 2024 (35th Week)

Disease	No. of Cases by Province										Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	N	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	00	01	00	00	00	00	00	00	01	02	01	50	65	-35.9 %	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	00	00	02	02	00	00	02	00	01	06	06	196	161	22.6 %	
Measles	01	00	00	00	00	00	00	00	00	01	40	283	371	-14.8 %	
Rubella	00	00	00	00	00	00	00	00	00	00	00	02	03	-33.3 %	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	06	-16.6 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	06	02	200 %	
Whooping Cough	01	00	00	01	00	00	00	00	00	02	00	41	06	550 %	

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

# Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

## ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10